ScoreWhy is Allergy Therapeutics Plc ?
1
With a Negative Book Value, the company has a Weak Long Term Fundamental Strength
- Poor long term growth as Operating profit has grown by an annual rate -245.44% of over the last 5 years
- Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -8.18
2
Negative results in Jun 25
- OPERATING CASH FLOW(Y) Lowest at GBP -62.92 MM
- RAW MATERIAL COST(Y) Grown by 22.73% (YoY)
- CASH AND EQV(HY) Lowest at GBP 12.79 MM
3
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of 44.29%, its profits have risen by 8%
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is Allergy Therapeutics Plc for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
Allergy Therapeutics Plc
50.0%
-0.65
62.93%
FTSE 100
13.98%
1.15
13.60%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
-6.78%
EBIT Growth (5y)
-245.44%
EBIT to Interest (avg)
-8.18
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-2.41
Sales to Capital Employed (avg)
1.68
Tax Ratio
0.11%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0.95%
ROCE (avg)
5.14%
ROE (avg)
1.26%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-25.05
EV to EBIT
-25.45
EV to EBITDA
-29.66
EV to Capital Employed
53.70
EV to Sales
13.60
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-210.99%
ROE (Latest)
Negative BV
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
Bullish
Bullish
Bollinger Bands
Sideways
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Mildly Bearish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bullish
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend4What is working for the Company
NET PROFIT(HY)
Higher at GBP -27.32 MM
ROCE(HY)
Highest at 0%
-10What is not working for the Company
OPERATING CASH FLOW(Y)
Lowest at GBP -62.92 MM
RAW MATERIAL COST(Y)
Grown by 22.73% (YoY
CASH AND EQV(HY)
Lowest at GBP 12.79 MM
INTEREST(Q)
Highest at GBP 4.2 MM
Here's what is working for Allergy Therapeutics Plc
Net Profit
Higher at GBP -27.32 MM
than preceding 12 month period ended Jun 2025MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months
Net Profit (GBP MM)
Depreciation
Highest at GBP 2.24 MM
in the last five periodsMOJO Watch
The expenditure on assets done by the company may have gone into operation
Depreciation (GBP MM)
Here's what is not working for Allergy Therapeutics Plc
Operating Cash Flow
Lowest at GBP -62.92 MM and Fallen
In each year in the last three yearsMOJO Watch
The company's cash revenues from business operations are falling
Operating Cash Flows (GBP MM)
Interest
Highest at GBP 4.2 MM
in the last five periods and Increased by 41.85% (QoQ)MOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (GBP MM)
Cash and Eqv
Lowest at GBP 12.79 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is deteriorating
Cash and Cash Equivalents
Raw Material Cost
Grown by 22.73% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin
Raw Material Cost as a percentage of Sales
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
